Michael Korn, MD
Clinical Professor
Medicine
School of Medicine

He is principal investigator on clinical trials of novel anti-cancer agents as part of the Phase-I Clinical Trials program and leads trials in esophageal and gastric cancers., Dr. Korn's laboratory research focuses on systems biology and computational models of signal transduction in cancer, as well as design of rational combination therapies targeting receptor tyrosine kinase signaling, and the MAPK and PI3K pathways.

• A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
  Breast cancer research and treatment 2016 Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN
• A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM
• Esophageal and esophagogastric junction cancers, version 1.2015.
  Journal of the National Comprehensive Cancer Network : JNCCN 2015 Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, Das P, Denlinger C, Fanta P, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Jasperson K, …
• 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.
  Journal of gastrointestinal cancer 2014 Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP
• A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
  British journal of cancer 2013 Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK
• Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.
  Molecular cancer therapeutics 2013 Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM
• Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines.
  Journal of the National Comprehensive Cancer Network : JNCCN 2013 Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Meredith K, …
• Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
  Annals of oncology : official journal of the European Society for Medical Oncology 2013 Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP
• Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors.
  Physical biology 2012 Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P
• Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers.
  Physical biology 2012 Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, …
• Esophageal and esophagogastric junction cancers.
  Journal of the National Comprehensive Cancer Network : JNCCN 2011 Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Mulcahy MF, …
• ZEB1 limits adenoviral infectability by transcriptionally repressing the coxsackie virus and adenovirus receptor.
  Molecular cancer 2011 Lacher MD, Shiina M, Chang P, Keller D, Tiirikainen MI, Korn WM
• Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma.
  Journal of molecular medicine (Berlin, Germany) 2011 Mirzoeva OK, Hann B, Hom YK, Debnath J, Aftab D, Shokat K, Korn WM
• A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition.
  PLoS computational biology 2011 Bagheri N, Shiina M, Lauffenburger DA, Korn WM
• Gastric cancer.
  Journal of the National Comprehensive Cancer Network : JNCCN 2010 Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy…
• A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
  Cancer chemotherapy and pharmacology 2010 Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA
• A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM
• RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses.
  Cancer gene therapy 2009 Shiina M, Lacher MD, Christian C, Korn WM
• Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.
  Cancer research 2009 Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ,…
• Esophageal erosion 9 years after anterior cervical plate implantation.
  Surgical neurology 2008 Lu DC, Theodore P, Korn WM, Chou D
• Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver.
  Cancer gene therapy 2006 Au T, Thorne S, Korn WM, Sze D, Kirn D, Reid TR
• Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation.
  Cancer gene therapy 2006 Korn WM, Macal M, Christian C, Lacher MD, McMillan A, Rauen KA, Warren RS, Ferrell L
• Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition.
  Cancer research 2006 Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, Oft M, Balmain A, Akhurst RJ, Korn WM
• Prevention and management of early esophageal cancer.
  Current treatment options in oncology 2004 Korn WM
• Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells.
  Cancer research 2003 Anders M, Christian C, McMahon M, McCormick F, Korn WM
• Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor.
  Proceedings of the National Academy of Sciences of the United States of America 2003 Anders M, Hansen R, Ding RX, Rauen KA, Bissell MJ, Korn WM
• ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.
  British journal of cancer 2002 Ries S, Korn WM
• Moving toward an understanding of the metastatic process in hepatocellular carcinoma.
  World journal of gastroenterology 2001 Korn WM
• Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization.
  Genes, chromosomes & cancer 1999 Korn WM, Yasutake T, Kuo WL, Warren RS, Collins C, Tomita M, Gray J, Waldman FM
• Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer.
  Anti-cancer drugs 1998 Klaassen U, Wilke H, Weyhofen R, Harstrick A, Eberhardt W, Müller C, Korn M, Hanske M, Diergarten K, Seeber S
• Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer.
  Oncology (Williston Park, N.Y.) 1997 Klaassen U, Wilke H, Müller C, Borquez D, Korn M, Achterrath W, Harstrick A, Diergarten K, Seeber S
• Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil.
  Anti-cancer drugs 1997 Strumberg D, Harstrick A, Klaassen U, Müller C, Eberhardt W, Korn MW, Wilke H, Seeber S
• Use of fluorescence in situ hybridization and comparative genomic hybridization in the cytogenetic analysis of testicular germ cell tumors and uveal melanomas.
  Cancer genetics and cytogenetics 1997 Becher R, Korn WM, Prescher G
• Detection of chromosomal DNA gains and losses in testicular germ cell tumors by comparative genomic hybridization.
  Genes, chromosomes & cancer 1996 Korn WM, Oide Weghuis DE, Suijkerbuijk RF, Schmidt U, Otto T, du Manoir S, Geurts van Kessel A, Harstrick A, Seeber S, Becher R
• Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer.
  European journal of cancer (Oxford, England : 1990) 1996 Klaassen U, Wilke H, Strumberg D, Eberhardt W, Korn M, Seeber S
• Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer.
  The Journal of infusional chemotherapy 1996 Wilke H, Korn M, Vanhöfer U, Fink U, Stahl M, Preusser P, Köhne C, Klassen U, Harstrick A, Schmoll HJ, Seeber S